AUL
MIRM icon

AlphaGrep UK Ltd’s Mirum Pharmaceuticals MIRM Stock Holding History

AlphaGrep UK Ltd’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,735
Closed -$295K – 877
2025
Q4 		$295K Buy
+3,735
New +$268K 0.1% 439

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

AlphaGrep UK Ltd's MIRM Position: Q1 2026 in Review

AlphaGrep UK Ltd sold out of Mirum Pharmaceuticals (MIRM) in Q1 2026, closing a stake of 3,735 shares — an estimated $295K sold.

AlphaGrep UK Ltd first reported a position in MIRM in Q4 2025 and held it in 1 quarter. The position peaked at $295K in Q4 2025. 311 funds tracked by Wall St. Rank hold MIRM as of Q1 2026.

  • AlphaGrep UK Ltd reported no remaining Mirum Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • AlphaGrep UK Ltd sold 3,735 Mirum Pharmaceuticals shares in Q1 2026, an estimated $295K.
  • AlphaGrep UK Ltd first reported a position in Mirum Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • AlphaGrep UK Ltd's Mirum Pharmaceuticals position peaked at $295K in Q4 2025.
  • 311 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q1 2026.

Based on AlphaGrep UK Ltd's 13F filing for Q1 2026, filed 13 Aug 2026.